Alzheimer's and Dementia

Journal

Publication Venue For

  • Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans..  18:1248-1259. 2022
  • The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study.  18:434-444. 2022
  • Association between cancer treatment and progression of all-cause dementia.  17:e054164. 2021
  • Dementia care in diverse older adults in the Deep South and the rest of the United States.  17:e054038. 2021
  • Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood.  17:e050692. 2021
  • Developing a functionally valid model of the TREM2-APOE complex to better understand its role in Alzheimer's disease.  17:e056092. 2021
  • Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.  17:e055982. 2021
  • Factors influencing medication adherence among U.S. Medicare beneficiaries with Alzheimer’s disease and related dementia (ADRD).  17. 2021
  • Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration.  17:e052495. 2021
  • Identification of cis-regulatory elements associated with MAPT expression in human induced pluripotent stem cell derived neural cells.  17:e058349. 2021
  • Modeling AD-related metabolic impairments in the TgF344-AD rat model.  17:e058576. 2021
  • Functional insights from biophysical study of TREM2 interactions with apoE and Aβ1-42.  17:475-488. 2021
  • Daily stressful experiences, depressive symptoms, and behavioral responses of ADRD family caregivers.  16. 2020
  • Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.  16:91-105. 2020
  • Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.  16:11-21. 2020
  • Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint..  16:11-21. 2020
  • Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.  16:49-59. 2020
  • Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort.  16:60-70. 2020
  • Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases.  16:118-130. 2020
  • Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.  16:37-48. 2020
  • Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium.  16:79-90. 2020
  • Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.  16:106-117. 2020
  • Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr).  15:709-719. 2019
  • Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study.  15:273-281. 2019
  • Transethnic genome-wide scan identifies novel Alzheimer's disease loci.  13:727-738. 2017
  • Glucose level decline precedes dementia in elderly African Americans with diabetes.  13:111-118. 2017
  • Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk.  12:233-243. 2016
  • Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses.  11:1439-1451. 2015
  • O3‐06‐01: Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.  11. 2015
  • Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.  10:349-359. 2014
  • Implications of early treatment among Medicaid patients with Alzheimer's disease.  10:214-224. 2014
  • Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development.  9:176-188. 2013
  • The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier).  9:189-198. 2013
  • Erratum: Estimating power with effect size versus slope differences: Both means and variance matter (Alzheimer's and Dementia (2011) 7 (247-249)).  7:556. 2011
  • Estimating power with effect size versus slop differences: Both means and variance matter.  7:247-249. 2011
  • Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.  6:367-377. 2010
  • Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.  4:421-427. 2008